FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1498491692> ?p ?o ?g. }

• W1498491692 abstract "The prospect of effective immunotherapies for the treatment of patients with cancer is now becoming a clinical reality. Different major phenotypes of tumor microenvironment are emerging and could require distinct immunotherapeutic interventions for maximal therapeutic effect. In the T-cell infiltrated tumors context, monoclonal antibody blocking the PD-1/PD-L1 pathway, like nivolumab or lambrolizumab, have shown very promising clinical efficacy for patients with metastatic melanoma (MM), Non Small Cell Lung cancer and renal cell carcinoma (1, 2). Recently, the combination of nivolumab and ipilimumab (anti CTLA-4) has demonstrated a strong synergy in MM patients (3). Thus, blocking peripheral tolerance mechanisms such as CTLA-4 and PD1 molecules seems to be a very promising strategy to cure such cancers. Many combinations with other immunotherapeutic interventions seem encouraging to be evaluated in early clinical trials. Leveraging or consolidating the driving forces between the efficacy of such checkpoint inhibitors with novel activating or inhibiting immunomodulatory agents is crucial and has to be based on relevant pharmacological and preclinical models. RLI is a sushi-IL-15Rα/IL-15 fusion protein that mimics the IL-15 transpresentation (4). In this study, the immunomodulatory activities induced by RLI were evaluated in vivo in mice and ex-vivo on human samples. We showed that RLI induced a strong expansion and increased effector functions and differentiation of NK and CD8+ T cells without any induction/activation of regulatory CD4+ T cells (Treg). Comparison of equimolar doses of RLI, IL-15 and IL-2, led to the conclusion that RLI is much more effective than IL-15 for the induction of NK and CD8+ T cells and increased the ratio of NK to Treg cells. Beside, RLI appeared as a safe, specific and potent IL-15Rβ/γ receptor agonist. We then investigated potential synergy with anti-PD1 treatment in the CT26 preclinical mouse tumor model. Anti-PD1 and RLI concomitant treatment induced 31% of complete tumor regressions (CR) in the tumor model, while anti-PD1 as standalone treatment induced 6% of CR. The underlying mechanisms of this synergy will be presented during the AACR meeting. Altogether, this work provides evidence that RLI can enhance anti-tumor activity of anti-PD1 treatment. As RLI was shown to present a favorable safety profile in different animal species, these results are very encouraging and warrant its investigation in early clinical trials in the coming years. (1) Topalian SL et al. N Engl J Med. 2012 (2) Hamid O et al. N Engl J Med. 2013 (3) Wolchok JD et al. N Engl J Med. 2013 (4) Mortier E, et al. J Biol Chem. 2006 Citation Format: Melanie Desbois, Coralie Beal, Clelia Coutzac, Magali Terme, Geraldine Teppaz, Sebastien Morisseau, David Bechard, Erwan Mortier, Nathalie Chaput. RLI, a sushi-IL-15Rα/IL-15 fusion protein, is a potent immunomodulatory agent on NK and CD8+ T cells and synergizes with anti-PD1 treatment in preclinical mouse tumor models. [abstract]. In: Proceedings of the 105th Annual Meeting of the American Association for Cancer Research; 2014 Apr 5-9; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2014;74(19 Suppl):Abstract nr 2577. doi:10.1158/1538-7445.AM2014-2577" @default.
• W1498491692 created "2016-06-24" @default.
• W1498491692 creator A5012214419 @default.
• W1498491692 creator A5020466887 @default.
• W1498491692 creator A5023263627 @default.
• W1498491692 creator A5031362151 @default.
• W1498491692 creator A5031759048 @default.
• W1498491692 creator A5056728439 @default.
• W1498491692 creator A5065739297 @default.
• W1498491692 creator A5076032074 @default.
• W1498491692 creator A5087659024 @default.
• W1498491692 date "2014-09-30" @default.
• W1498491692 modified "2023-10-01" @default.
• W1498491692 title "Abstract 2577: RLI, a sushi-IL-15Rα/IL-15 fusion protein, is a potent immunomodulatory agent on NK and CD8+ T cells and synergizes with anti-PD1 treatment in preclinical mouse tumor models" @default.
• W1498491692 doi "https://doi.org/10.1158/1538-7445.am2014-2577" @default.
• W1498491692 hasPublicationYear "2014" @default.
• W1498491692 type Work @default.
• W1498491692 sameAs 1498491692 @default.
• W1498491692 citedByCount "0" @default.
• W1498491692 crossrefType "proceedings-article" @default.
• W1498491692 hasAuthorship W1498491692A5012214419 @default.
• W1498491692 hasAuthorship W1498491692A5020466887 @default.
• W1498491692 hasAuthorship W1498491692A5023263627 @default.
• W1498491692 hasAuthorship W1498491692A5031362151 @default.
• W1498491692 hasAuthorship W1498491692A5031759048 @default.
• W1498491692 hasAuthorship W1498491692A5056728439 @default.
• W1498491692 hasAuthorship W1498491692A5065739297 @default.
• W1498491692 hasAuthorship W1498491692A5076032074 @default.
• W1498491692 hasAuthorship W1498491692A5087659024 @default.
• W1498491692 hasConcept C150903083 @default.
• W1498491692 hasConcept C167672396 @default.
• W1498491692 hasConcept C203014093 @default.
• W1498491692 hasConcept C207001950 @default.
• W1498491692 hasConcept C2776090121 @default.
• W1498491692 hasConcept C2777701055 @default.
• W1498491692 hasConcept C2780030458 @default.
• W1498491692 hasConcept C2780674031 @default.
• W1498491692 hasConcept C2781433595 @default.
• W1498491692 hasConcept C502942594 @default.
• W1498491692 hasConcept C71924100 @default.
• W1498491692 hasConcept C86803240 @default.
• W1498491692 hasConcept C8891405 @default.
• W1498491692 hasConcept C98274493 @default.
• W1498491692 hasConceptScore W1498491692C150903083 @default.
• W1498491692 hasConceptScore W1498491692C167672396 @default.
• W1498491692 hasConceptScore W1498491692C203014093 @default.
• W1498491692 hasConceptScore W1498491692C207001950 @default.
• W1498491692 hasConceptScore W1498491692C2776090121 @default.
• W1498491692 hasConceptScore W1498491692C2777701055 @default.
• W1498491692 hasConceptScore W1498491692C2780030458 @default.
• W1498491692 hasConceptScore W1498491692C2780674031 @default.
• W1498491692 hasConceptScore W1498491692C2781433595 @default.
• W1498491692 hasConceptScore W1498491692C502942594 @default.
• W1498491692 hasConceptScore W1498491692C71924100 @default.
• W1498491692 hasConceptScore W1498491692C86803240 @default.
• W1498491692 hasConceptScore W1498491692C8891405 @default.
• W1498491692 hasConceptScore W1498491692C98274493 @default.
• W1498491692 hasLocation W14984916921 @default.
• W1498491692 hasOpenAccess W1498491692 @default.
• W1498491692 hasPrimaryLocation W14984916921 @default.
• W1498491692 hasRelatedWork W2049601932 @default.
• W1498491692 hasRelatedWork W2317505050 @default.
• W1498491692 hasRelatedWork W2486771387 @default.
• W1498491692 hasRelatedWork W2547939689 @default.
• W1498491692 hasRelatedWork W2548161278 @default.
• W1498491692 hasRelatedWork W2593626338 @default.
• W1498491692 hasRelatedWork W2740653681 @default.
• W1498491692 hasRelatedWork W2742141246 @default.
• W1498491692 hasRelatedWork W2786100538 @default.
• W1498491692 hasRelatedWork W2790270315 @default.
• W1498491692 hasRelatedWork W2883800164 @default.
• W1498491692 hasRelatedWork W2912011751 @default.
• W1498491692 hasRelatedWork W2912427403 @default.
• W1498491692 hasRelatedWork W2918157257 @default.
• W1498491692 hasRelatedWork W2955170235 @default.
• W1498491692 hasRelatedWork W3028071113 @default.
• W1498491692 hasRelatedWork W3082220598 @default.
• W1498491692 hasRelatedWork W3082234355 @default.
• W1498491692 hasRelatedWork W3104437666 @default.
• W1498491692 hasRelatedWork W3111773541 @default.
• W1498491692 isParatext "false" @default.
• W1498491692 isRetracted "false" @default.
• W1498491692 magId "1498491692" @default.
• W1498491692 workType "article" @default.